Last updated: March 2, 2026
What is NDC 00065-0660?
NDC 00065-0660 is a proprietary drug product marketed as Liraglutide (brand Victoza). It is indicated for type 2 diabetes management, weight management, and cardiovascular risk reduction. Manufactured by Novo Nordisk, the medication’s formulations include prefilled pens with doses typically ranging from 0.6 mg to 1.8 mg, with higher doses authorized for specific indications.
Current Market Environment
Market Size and Growth
The global diabetes drug market was valued at approximately $60 billion in 2022, with a compound annual growth rate (CAGR) of around 6% projected through 2030 [1]. Liraglutide contributes significantly to this, with sales exceeding $4 billion annually.
Current adoption hinges on:
- The increasingly prevalent type 2 diabetes cases [2].
- The expanding use for weight management, driven by obesity rates rising globally [3].
- The cardiovascular benefits substantiated by clinical trials, encouraging broader prescription [4].
Competitive Landscape
Major competitors:
- Semaglutide (Ozempic, Wegovy) by Novo Nordisk.
- Dulaglutide (Trulicity) by Eli Lilly.
- Exenatide (Byetta, Bydureon) by AstraZeneca.
Pricing and Reimbursement Trends
Average wholesale price (AWP): Approximately $900–$1,200 per month, based on dosage and region [5].
Reimbursement policies favor newer drugs with proven cardiovascular benefits and weight-loss effects, putting pressure on older formulations.
Price Projections (Next 5 Years)
Factors Impacting Price
- Patent Status: Liraglutide’s patent protection expires in 2027, opening the market for biosimilars, which typically reduce prices by 30-50% [6].
- Biosimilar Entry: Expected biosimilars could lead to price erosion starting 2027.
- Regulatory Changes: Potential policy shifts favoring cost-effective generics/biosimilars.
Forecast
| Year |
Estimated Average Monthly Price |
Key Factors |
| 2023 |
$1,000 |
Stable, high demand, brand dominance |
| 2024 |
$950 |
Competitive pressure intensifies |
| 2025 |
$900 |
Increasing market saturation |
| 2026 |
$850 |
Approaching biosimilar approval |
| 2027+ |
$600–$750 |
Biosimilar competition; price declines |
Note: Prices are approximate and vary based on geographic region, payer arrangements, and formulation specifics.
Biosimilar Impact
Biosimilars approved in the U.S. could reduce prices by 50%, offering entry as early as 2027, depending on regulatory approval timelines and market acceptance.
Risks and Opportunities
- Risks: Patent litigation delays, slow biosimilar uptake, regulatory hurdles.
- Opportunities: Expanded indication approvals, combination therapies, evolving reimbursement policies favoring outcomes-based models.
Summary
NDC 00065-0660 (Liraglutide) maintains a high market value driven by clinical benefits and broadening indications. The market is poised for significant price reductions starting around 2027 due to biosimilar competition. Short-term stability is expected, with long-term consolidation likely resulting in lower prices.
Key Takeaways
- The drug's market remains robust, with high demand for diabetes and weight management therapies.
- Price projections indicate a decline from approximately $900–$1,200/month in 2023 to $600–$750/month post-biosimilar entry.
- Patent expiry in 2027 will be the critical inflection point, enabling biosimilar competition.
- Market penetration of biosimilars and regulatory developments will shape future pricing strategies.
- Novo Nordisk’s innovation pipeline could offset some revenue impacts through new formulations or combination products.
FAQs
1. When will biosimilars for liraglutide become available?
Approval is anticipated post-patent expiry around 2027, with some biosimilar applications already under review.
2. How does the price trend differ across geographic regions?
U.S. prices tend to be higher due to insurance and reimbursement structures, while prices in Europe and emerging markets are generally lower.
3. Are there new indications that could sustain higher prices?
Yes. Approval for additional uses such as cardiovascular disease outcomes and obesity could extend revenue streams.
4. What is the impact of patent litigation on price timelines?
Patent disputes may delay biosimilar entry, potentially preserving higher prices beyond 2027.
5. How might healthcare policies influence pricing?
Policies emphasizing cost-effectiveness and biosimilar adoption could accelerate price reductions.
References
[1] Grand View Research. (2022). Global Diabetes Drugs Market Size, Share & Trends.
[2] World Health Organization. (2021). Diabetes Fact Sheet.
[3] CDC. (2022). Adult Obesity Prevalence.
[4] Marso SP, et al. (2016). Cardiovascular Outcomes with Liraglutide in Type 2 Diabetes. N Engl J Med, 375(4), 311-322.
[5] GoodRx. (2022). Average Wholesale Prices for Liraglutide.
[6] FDA. (2022). Biosimilar Approval Pathways.
